TCRX — Tscan Therapeutics Share News
0.000.00%
Last trade - 00:00- $13.21m
- -$54.17m
- $10.33m
Brief: Tscan Therapeutics Reports Fourth Quarter And 2022 Financial Results
U.S. STOCKS ON THE MOVE-Pliant Therapeutics, Skechers USA, Inspira Tech
U.S. STOCKS ON THE MOVE-Pliant Therapeutics , Wayfair, Evoqua Water Technologies
U.S. STOCKS ON THE MOVE-BiondVax Pharma, Evoqua Water, Wayfair
TScan Therapeutics up on FDA nod to initiate study of cancer therapies
Brief: TScan Therapeutics Announces FDA Clearance Of Three Investigational NDA
Brief: Tscan Therapeutics Announces 2023 Clinical Plans
Brief: Tscan Therapeutics Presents Phase 1 Umbrella Trial In Progress On Ha-1 (Tsc-100) And Ha-2 (Tsc-101) At The 64Th American Society Of Hematology Annual Meeting 2022
Brief: TScan Therapeutics Presents Preclinical Data For Solid Tumor Program
Brief: Tscan Therapeutics Reports Third Quarter 2022 Financial Results And Provides Business Update
Brief: Tscan Therapeutics Secures Convertible Debt Facility For Up To $60 Million With K2 Healthventures
Brief: Tscan Therapeutics reports Q2 results
Brief: TScan Therapeutics Announces Publication In Cell Highlighting Discovery Of Tumor Antigens, TCRs For Treatment Of Solid Tumors Using Foundational Screening Technology
Brief: Tscan Therapeutics Appoints Debora Barton As Chief Medical Officer
Brief: TScan Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TSC-101
Brief: Tscan Therapeutics Reports First Quarter 2022 Financial Results
Brief: TScan Therapeutics Reports Full Year 2021 Financial Results And Highlights Key 2022 Priorities
Brief: TScan Therapeutics Announces FDA Clearance Of Investigational New Drug Application For TSC-100 For The Treatment Of Hematologic Malignancies
Brief: TScan Outlines 2022 Priorities As Programs Enter Clinic